Cassava Sciences Inc vs iShares MSCI India ETF — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while iShares MSCI India ETF trades at $49.94. The key difference: iShares MSCI India ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | INDA | |
|---|---|---|
Market Cap | $47.75M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $4.64 | $55.29 |
52-Week Low | $0.87 | $45.42 |
Enterprise Value | -$34.93M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
INDA trades at $49.95, down 0.38% on the day, with technical indicators showing a bullish trend supported by moving averages but neutral oscillators. The ETF reflects exposure to India's economy, which grew 7.8% in Q1 2026 (CNBC, 2026-06-05), though financial ratios are unavailable. Recent news highlights sector-specific challenges, including IT weakness and pharmaceutical export hurdles.
The outlook for INDA is mixed, with India's robust economic growth offering long-term potential, but near-term risks from foreign outflows, geopolitical tensions, and sectoral headwinds may pressure performance. Investors should weigh macroeconomic resilience against volatility in key industries like technology and pharma.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →